BIAXIN XL
LOE ApproachingNDAORALTABLET
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIAXIN XL is an extended-release oral tablet antibiotic approved in 1993 for bacterial infections. The generic name and specific mechanism of action are not provided in available data, but the product is classified as a small-molecule NDA. It represents a mature therapeutic option in the antibiotic market.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential contraction in brand team size and shift toward managed care and pricing roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BIAXIN XL roles are limited and declining given LOE approaching status. Career opportunities center on defensive strategies, managed care negotiations, and potential generic transition planning rather than growth initiatives. This product represents a consolidation or legacy support function rather than a growth vehicle.
Brand ManagerProduct Manager
Worked on BIAXIN XL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.